Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Siglec-15: An Attractive Immunotherapy Target.

Literature DB >> 31806628

Siglec-15: An Attractive Immunotherapy Target.

Abstract

Siglec-15, which selectively drives immunosuppression in the tumor microenvironment, has emerged as a viable therapeutic target. In a phase I trial of NC318, a Siglec-15 antibody, encouraging efficacy was seen, including a complete response in non-small cell lung cancer refractory to PD-1 blockade. ©2020 American Association for Cancer Research.

Entities: Disease Gene

Year: 2019 PMID： 31806628 DOI： 10.1158/2159-8290.CD-NB2019-136

Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397

Keyword Cloud
Cited

11 in total

1. Pan-cancer Bioinformatics Analysis of the Double-edged Role of Hypoxia-inducible Factor 1α (HIF-1α) in Human Cancer.

Authors: R U Li; Kang Tang; Qian Li
Journal: Cancer Diagn Progn Date: 2022-03-03

Review 2. Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing.

Authors: Rilan Bai; Jiuwei Cui
Journal: Front Immunol Date: 2022-06-27 Impact factor: 8.786

3. Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma.

Authors: Xiaofeng Hou; Chao Chen; Xiaodong He; Xiabin Lan
Journal: Dis Markers Date: 2022-06-20 Impact factor: 3.464

4. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.

Authors: Guangchun Han; Guoliang Yang; Dapeng Hao; Yang Lu; Kyaw Thein; Benjamin S Simpson; Jianfeng Chen; Ryan Sun; Omar Alhalabi; Ruiping Wang; Minghao Dang; Enyu Dai; Shaojun Zhang; Fengqi Nie; Shuangtao Zhao; Charles Guo; Ameer Hamza; Bogdan Czerniak; Chao Cheng; Arlene Siefker-Radtke; Krishna Bhat; Andrew Futreal; Guang Peng; Jennifer Wargo; Weiyi Peng; Humam Kadara; Jaffer Ajani; Charles Swanton; Kevin Litchfield; Jordi Rodon Ahnert; Jianjun Gao; Linghua Wang
Journal: Nat Commun Date: 2021-09-23 Impact factor: 17.694

Review 5. Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.

Authors: Xueyin Zhou; Ting Ren; Hongyuan Zan; Chunyan Hua; Xufeng Guo
Journal: Front Immunol Date: 2022-05-20 Impact factor: 8.786

6. Glycosylation of Siglec15 promotes immunoescape and tumor growth.

Authors: Yun-Long Wang; Ming-Biao Wei; Wan-Wen Zhao; Li-Li Feng; Xin-Ke Yin; Shao-Mei Bai; Xiang-Bo Wan; Mien-Chie Hung; Andrew Z Zou; Michael H Wang; Jian Zheng; Caolitao Qin; Xin-Juan Fan
Journal: Am J Cancer Res Date: 2021-05-15 Impact factor: 6.166

Siglec-15: An Attractive Immunotherapy Target.

1. Pan-cancer Bioinformatics Analysis of the Double-edged Role of Hypoxia-inducible Factor 1α (HIF-1α) in Human Cancer.

Review 2. Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing.

3. Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma.

4. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.

Review 5. Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.

6. Glycosylation of Siglec15 promotes immunoescape and tumor growth.

Review 7. Emerging therapeutic agents for advanced non-small cell lung cancer.

8. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.

9. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.

10. Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway.